Completed NA INTERVENTIONAL 1-arm NCT04945811

Role of Interleukin-6 and Procalcitonin as Novel Inflammatory Biomarkers in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta

Role of Interleukin-6 and Procalcitonin in Evaluating COVID 19 Disease Severity - an Experience at CMH Quetta

Sponsor: FARAH AFZAL

Interventions Interlukein 6 and procalcitonin serum levels

Updated 3 times since 2021 Last updated: Jun 29, 2021 Started: Apr 1, 2020 Primary completion: May 15, 2021 Completion: May 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04945811, this NA trial focuses on Covid19 Positive Patients and remains completed. Sponsored by FARAH AFZAL, it has been updated 3 times since 2020, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Sep 2021 — Jul 2024 [monthly]

Completed NA

First recorded

Apr 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

FARAH AFZAL

Data source: Combined Military Hospital, Pakistan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Quetta, Pakistan